Peter Markham, CBSET Founder, CEO and President, and Celia Belline, CILcare Founder and CEO discuss “New Medical Approaches to Treating Hearing Loss” In this interview with Hearing Health Matters, Celia and Peter recount their successful strategic collaboration over the last 5 years, and their recent award for their innovative preclinical auditory services in the 3rd […]
LEXINGTON, MA, USA, October 21st, 2022 — CILcare, a leading R&D services company dedicated to ear disorders, announced today that the company, and its partner CBSET Inc., a not-for-profit translational research institute, have been recognized for their innovative preclinical auditory services in the third annual Hearing Technology Innovator Awards™. Through the annual awards program, Hearing […]
“Our study has documented, for the first time, the distributionof nerves and adjacent anatomies surrounding human hepatic arteries. This is the foundation for the development of catheter-based denervation technologies, providing invaluable guidance on the preferred treatment locations and depths in order to be effective,” said Dr. Rami Tzafriri, Director of Research & Innovation for CBSET […]
We are pleased to share the replay of the Talking Tox Webinar, which took place as part of ACT’s 42nd Virtual Annual Meeting, featuring experts from the CBSET, CILcare and the FDA. View the webinar replay to learn more about preclinical ototoxicity evaluation: Ototoxicity resulting in inner ear damage is a leading cause of acquired […]
How one medtech startup and its preclinical research partner overcame pandemic-related obstacles to continue its medical device research project. Prior to COVID-19, VentureMed was on a roll. The Minneapolis, MN-based company’s first-generation Flex Vessel Prep System had demonstrated promising clinical performance following FDA clearance and the company was preparing to introduce an improved second-generation device. […]
“Auditory research studies are typically performed using rodent models. Yet, owing to their size, implant studies often require a larger species with middle and inner ear anatomy more relevant to humans,” said Misty Williams-Fritze, DVM, MS, DACLAM, CBSET, co-lead researcher. Lexington, MA — February 19, 2021 — CBSET Inc., a not-for-profit translational research institute, announced […]
Trio of studies demonstrate that FLEX Vessel Prep System safely and effectively modifies obstructive plaque to facilitate delivery of definitive therapies MINNEAPOLIS, Jan. 27, 2021 — VentureMed Group, Inc. (VentureMed), a privately-held medical device innovator, announced today that data from three studies evaluating the use of its FLEX Vessel Prep (VP) System were presented during […]
Montpellier, France — January 14th, 2021 — CILcare, the world-leading CRO specialized in the field of hearing, recently had the immense pleasure of welcoming Dr. Mathieu Schué to the team as Project Director of Drug Development & Translational Research. In this role, Mathieu Schué will dive into CILcare’s preclinical models and read-outs, validate reference compounds […]
Montpellier, France — November 9, 2020 — CBSET partner CILcare, a world leading CRO entirely dedicated to ear disorders, announced today the opening of a new subsidiary in Copenhagen, Denmark. Already established in the US, the French company is joining the Medicon Valley Alliance, a leading international life-sciences cluster in Northern Europe. This second subsidiary […]
September 30, 2020—CBSET Inc., a not-for-profit translational research institute, announced the publication of a preclinical study, “Balloon-based drug coating delivery to the artery wall is dictated by coating micro-morphology and angioplasty pressure gradients,” by Abraham R. Tzafriri, PhD, et al, online ahead of print in the Journal of Biomaterials.